Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J.P. Morgan Notebook, Jan. 12: Biogen, Novartis, Celgene

This article was originally published in The Pink Sheet Daily

Executive Summary

Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first day of the 2015 J.P. Morgan Healthcare Conference in San Francisco.

You may also be interested in...

Celgene’s Oral Mongersen Could Be Game-Changer In Crohn’s Disease

New England Journal of Medicine editorial says that if Phase II results for Celgene’s oral antisense candidate mongersen (GED-0301) are confirmed, the drug’s durable effect “would be unprecedented and would represent a first step toward curing the disease.”

Novartis Execs Highlight Cosentyx, LCZ696 As Key 2015 Launches

The swapping of product portfolios with other companies remains on track at Switzerland’s big pharma Novartis, despite a seven-percentage-point sales erosion due to emerging generic competition during 2014, and more recent currency turmoil in its home country.

Changing Face Of ‘Me Too’ Drugs On Display In 2014 NME Approvals

As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts